ReviewCureus2025
Optimizing Membrane Composition With C15 and Choline: A Novel Hypothesis to Mitigate Cancer Risk.
Review in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cancer incidence has dramatically increased over the past centuries, paralleling dietary shifts in Western nations. This narrative review evaluates whether excess dietary linoleic acid (LA) drives tumor initiation through membrane-mediated oxidative stress and chronic inflammation, and whether pentadecanoic acid (C15:0) and choline can restore membrane resilience and attenuate cancer risk. Historical epidemiological data and mechanistic studies reveal that rising cancer incidence tracks population-level LA exposure, while C15:0 and choline consumption have declined. In cellular and animal models, LA oxidation products activate pro-inflammatory and anti-apoptotic pathways. Conversely, C15:0 resists peroxidation and preserves mitochondrial integrity, while choline normalizes membrane fluidity. A precision-nutrition strategy restricting LA while fortifying C15:0 and choline offers a biochemically coherent complement to conventional oncology. Prospective clinical trials are warranted to validate whether correcting this lipid imbalance can reduce cancer incidence.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.